Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$6.54
-0.22 (-3.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-21.0M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.6%
↓Gross Margin
54.2%
↑Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.5%
FCF CAGR
—
FCF margin
6.2%
FCF / Net income
-0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $466.1M · net income $-230.1M · FCF $29.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $466.1M | $466.1M | $469.5M | $689.3M | $535.7M |
| Net Income | $-230.1M | $-230.1M | $-215.4M | $-13.6M | $-187.6M |
| EBITDA | $-173.8M | $-173.8M | $-139.3M | $93.0M | $-143.9M |
| EPS | -0.51 | -0.51 | -0.48 | -0.03 | -0.42 |
| Gross Margin | 54.2% | 54.2% | 55.0% | 57.3% | 50.8% |
| Operating Margin | -34.3% | -34.3% | -27.5% | 4.5% | -22.7% |
| Net Margin | -49.4% | -49.4% | -45.9% | -2.0% | -35.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.46 | 0.38 | 0.44 |
| Current Ratio | 0.52 | 0.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $29.1M | $29.1M | $-21.0M | $-66.9M | $-15.8M |
| Returns | |||||
| ROE | -25.6% | -25.6% | -19.3% | -1.0% | -14.3% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 31.83 | — |
| P/B | 3.31 | 3.31 | 1.87 | 1.97 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | -0.7% | -0.7% | -31.9% | 28.7% | — |
| EPS Growth | -5.9% | -5.9% | -1475.6% | 92.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.48 → -0.51
Residual
+26.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.